These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 23259737)

  • 21. Natural polymorphisms of integrase among HIV type 1-infected South African patients.
    Fish MQ; Hewer R; Wallis CL; Venter WD; Stevens WS; Papathanasopoulos MA
    AIDS Res Hum Retroviruses; 2010 Apr; 26(4):489-93. PubMed ID: 20377427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In-vivo selection of the mutation F121Y in a patient failing raltegravir containing salvage regimen.
    Souza Cavalcanti J; Minhoto Lança A; de Paula Ferreira JL; da Eira M; de Souza Dantas DS; de Macedo Brígido LF
    Antiviral Res; 2012 Jul; 95(1):9-11. PubMed ID: 22564967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen.
    Charpentier C; Malet I; Andre-Garnier E; Storto A; Bocket L; Amiel C; Morand-Joubert L; Tumiotto C; Nguyen T; Maillard A; Rodallec A; Leoz M; Montes B; Schneider V; Plantier JC; Dina J; Pallier C; Mirand A; Roussel C; Signori-Schmuck A; Raymond S; Calvez V; Delaugerre C; Marcelin AG; Descamps D
    J Antimicrob Chemother; 2018 Apr; 73(4):1039-1044. PubMed ID: 29342281
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients.
    Saladini F; Meini G; Bianco C; Monno L; Punzi G; Pecorari M; Borghi V; Di Pietro M; Filice G; Gismondo MR; Micheli V; Penco G; Carli T; De Luca A; Zazzi M;
    Clin Microbiol Infect; 2012 Oct; 18(10):E428-30. PubMed ID: 22716970
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.
    Requena S; Treviño A; Cabezas T; Garcia-Delgado R; Amengual MJ; Lozano AB; Peñaranda M; Fernández JM; Soriano V; de Mendoza C;
    J Antimicrob Chemother; 2017 Jul; 72(7):2083-2088. PubMed ID: 28369593
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation.
    Delelis O; Malet I; Na L; Tchertanov L; Calvez V; Marcelin AG; Subra F; Deprez E; Mouscadet JF
    Nucleic Acids Res; 2009 Mar; 37(4):1193-201. PubMed ID: 19129221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deep analysis of HIV-1 natural variability across HIV-1 variants at residues associated with integrase inhibitor (INI) resistance in INI-naive individuals.
    Llácer Delicado T; Torrecilla E; Holguín Á
    J Antimicrob Chemother; 2016 Feb; 71(2):362-6. PubMed ID: 26546669
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir.
    Canducci F; Ceresola ER; Saita D; Castagna A; Gianotti N; Underwood M; Burioni R; Lazzarin A; Clementi M
    J Antimicrob Chemother; 2013 Nov; 68(11):2525-32. PubMed ID: 23798668
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors.
    Scutari R; Alteri C; Vicenti I; Di Carlo D; Zuccaro V; Incardona F; Borghi V; Bezenchek A; Andreoni M; Antinori A; Perno CF; Cascio A; De Luca A; Zazzi M; Santoro MM;
    J Glob Antimicrob Resist; 2020 Mar; 20():163-169. PubMed ID: 31330378
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Absence of Integrase Strand Transfer Inhibitor Associated Resistance in Antiretroviral Therapy Naïve and Experienced Individuals from Western India.
    Karade S; Sen S; Sashindran VK
    AIDS Res Hum Retroviruses; 2019 Jun; 35(6):567-571. PubMed ID: 30793915
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic variation of the HIV-1 integrase region in newly diagnosed anti-retroviral drug-naïve patients with HIV/AIDS in Korea.
    Kim JY; Kim EJ; Choi JY; Kwon OK; Kim GJ; Choi SY; Kim SS
    Clin Microbiol Infect; 2011 Aug; 17(8):1155-9. PubMed ID: 20946407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unravelling the dynamics of selection of multiresistant variants to integrase inhibitors in an HIV-1-infected child using ultra-deep sequencing.
    Stefic K; Salmona M; Capitao M; Splittgerber M; Maakaroun-Vermesse Z; Néré ML; Bernard L; Chaix ML; Barin F; Delaugerre C
    J Antimicrob Chemother; 2017 Mar; 72(3):850-854. PubMed ID: 27999055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of primary resistance mutations to integrase inhibitors in treatment-naïve and -experienced patients infected with B and non-B HIV-1 variants.
    Gutiérrez C; Hernández-Novoa B; Pérez-Elías MJ; Moreno AM; Holguín A; Dronda F; Casado JL; Moreno S
    HIV Clin Trials; 2013; 14(1):10-6. PubMed ID: 23372110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection.
    Garrido C; Geretti AM; Zahonero N; Booth C; Strang A; Soriano V; De Mendoza C
    J Antimicrob Chemother; 2010 Feb; 65(2):320-6. PubMed ID: 20007331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of the HIV integrase genetic context on the phenotypic expression and in vivo emergence of raltegravir resistance mutations.
    Nguyen TT; Rato S; Molina JM; Clavel F; Delaugerre C; Mammano F
    J Antimicrob Chemother; 2015 Mar; 70(3):731-8. PubMed ID: 25336162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not.
    Ni XJ; Delelis O; Charpentier C; Storto A; Collin G; Damond F; Descamps D; Mouscadet JF
    Retrovirology; 2011 Aug; 8():68. PubMed ID: 21854605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short communication: analysis of the integrase gene from HIV type 1-positive patients living in a rural area of West Cameroon.
    Turriziani O; Montagna C; Falasca F; Bucci M; Russo G; Lichtner M; Sobze MS; Vullo V; Pistello M; Antonelli G
    AIDS Res Hum Retroviruses; 2012 Dec; 28(12):1729-33. PubMed ID: 22214532
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients.
    Fourati S; Charpentier C; Amiel C; Morand-Joubert L; Reigadas S; Trabaud MA; Delaugerre C; Nicot F; Rodallec A; Maillard A; Mirand A; Jeulin H; Montès B; Barin F; Bettinger D; Le Guillou-Guillemette H; Vallet S; Signori-Schmuck A; Descamps D; Calvez V; Flandre P; Marcelin AG;
    J Antimicrob Chemother; 2015 May; 70(5):1507-12. PubMed ID: 25558077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Natural polymorphisms of HIV-1 CRF01_AE integrase coding region in ARV-naïve individuals in Cambodia, Thailand and Vietnam: an ANRS AC12 working group study.
    Nouhin J; Donchai T; Hoang KT; Ken S; Kamkorn J; Tran T; Ayouba A; Peeters M; Chaix ML; Lien TX; Nerrienet E; Ngo-Giang-Huong N
    Infect Genet Evol; 2011 Jan; 11(1):38-43. PubMed ID: 21094281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients.
    Malet I; Wirden M; Fourati S; Armenia D; Masquelier B; Fabeni L; Sayon S; Katlama C; Perno CF; Calvez V; Marcelin AG; Ceccherini-Silberstein F
    J Antimicrob Chemother; 2011 Jul; 66(7):1481-3. PubMed ID: 21474479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.